Mps1-IN-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Mps1-IN-3
• 英文别名: 1-[3-methoxy-4-[[6-(2-propan-2-ylsulfonylanilino)-7H-purin-2-yl]amino]phenyl]piperidin-4-ol
• 化学式: C₂₆H₃₁N₇O₄S
• 分子量: 537.6
• InChiKey: OFRMASLPWOMYHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  154
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME
  申请人：Dana Farber Cancer Institute, Inc.

  公开号：EP3778604A1

  公开（公告）日：2021-02-17

  Compounds having the formula I, II, or III: are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.

  具有式 I、II 或 III 的化合物： 的化合物。本公开的化合物可用于治疗神经退行性疾病，如帕金森病。
• LRRK2 inhibitors and methods of making and using the same
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10913744B2

  公开（公告）日：2021-02-09

  Compounds having the formula I, II, or III: are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.

  具有式 I、II 或 III 的化合物： 的化合物。本公开的化合物可用于治疗神经退行性疾病，如帕金森病。
• Methods and medical uses
  申请人：Institute of Cancer Research: Royal Cancer Hospital (The)

  公开号：US11207321B2

  公开（公告）日：2021-12-28

  The invention described herein provides a method for the treatment of an oestrogen receptor positive breast cancer in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound capable of inhibiting MPS1, wherein: (i) said subject has previously been treated with a CDK4/6 inhibitor; and/or (ii) said breast cancer is resistant to treatment with a CDK4/6 inhibitor.

  本文所述的发明提供了一种治疗雌激素受体阳性乳腺癌的方法，该方法包括向所述受试者施用治疗有效量的能够抑制 MPS1 的化合物，其中： (i) 所述受试者之前曾接受过 CDK4/6 抑制剂的治疗；和/或 (ii) 所述乳腺癌对 CDK4/6 抑制剂的治疗具有耐药性。
• METHODS AND MEDICAL USES
  申请人：Institute of Cancer Research: Royal Cancer Hospital (The)

  公开号：US20200138815A1

  公开（公告）日：2020-05-07

  The invention described herein provides a method for the treatment of an oestrogen receptor positive breast cancer in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound capable of inhibiting MPS1, wherein: (i) said subject has previously been treated with a CDK4/6 inhibitor; and/or (ii) said breast cancer is resistant to treatment with a CDK4/6 inhibitor.
• [EN] LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME<br/>[FR] INHIBITEURS DE LRRK2 ET LEURS MÉTHODES DE PRODUCTION ET D'UTILISATION
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2016130920A2

  公开（公告）日：2016-08-18

  Compounds having the formula (I), (II), (III) are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.